https://doi.org/10.4081/hmr.v2i7.415

Azacytidine: first therapeutic opportunity for myelodysplastic syndromes

Vol. 2 No. 7: New Insights in Hematology, Venice (Italy), May 14-17, 2006
Published: June 8, 2009
Abstract Views: 208
PDF: 310
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

C Finelli
support@pagepress.org
C Bosi
G Martinelli
M Baccarani
Myelodysplastic syndromes (MDS) are clonal disorders characterized by ineffective hematopoiesis, wich can lead either to fatal cytopenia or acute myelogenous leukemia (AML). During the last 14 years, important progress has been made in the understanding of the biology and prognosis of MDS; risk-adapted treatment strategies were estabilished, according to the median age (60-75 years ) of MDS patients and the individual history of the desease (number of cytopenias, cytogenetic changes, transfusion requirements).

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Finelli, C., Bosi, C., Martinelli, G., & Baccarani, M. (2009). Azacytidine: first therapeutic opportunity for myelodysplastic syndromes. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.415
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).